AstraZeneca reports positive outcomes from trial of Imfinzi
AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
UBS Keeps Their Buy Rating on AstraZeneca (AZN)
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...